Chester County News and Community Website
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced the appointment of Jacqualyn (“Jackie”) Fouse, Ph.D., to its Board of Directors, bringing decades of leadership and expertise in the biotech …
Madrigal Pharmaceuticals Announces Changes to Board of Directors Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced its financial results for 2024, marking a pivotal year highlighted by the FDA approval and successful launch of Rezdiffra (resmetirom). Rezdiffra, …
Madrigal Pharmaceuticals Reports Strong 2024 Growth Fueled by Rezdiffra Launch Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced positive two-year results from the Phase 3 MAESTRO-NAFLD-1 trial, demonstrating the potential of Rezdiffra (resmetirom) to significantly reduce liver stiffness in …
Madrigal Pharmaceuticals Reports Promising Two-Year Results for MASH Therapy Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced its participation in the 45th Annual TD Cowen Health Care Conference, scheduled to take place on Tuesday, March 4, 2025, …
Madrigal Pharmaceuticals to Present at 45th Annual TD Cowen Health Care Conference Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced the release of its fourth-quarter and full-year 2024 financial results, scheduled for Wednesday, February 26, 2025, before the U.S. financial …
Madrigal Pharmaceuticals to Announce Q4 and Full-Year 2024 Results with Live Webcast Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has released a business update highlighting strong preliminary financial results for 2024 and the ongoing success of its breakthrough treatment, Rezdiffra™ (resmetirom), …
Madrigal Reports Robust 2024 Performance and Plans for Growth Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has reported its financial and operational achievements for the third quarter of 2024, highlighting robust net sales and strategic progress with its …
Madrigal Pharmaceuticals Announces Strong Q3 2024 Results and Strategic Advances Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has successfully completed enrollment for its MAESTRO-NASH OUTCOMES trial, a critical study evaluating the efficacy of resmetirom in patients with compensated NASH …
Madrigal Pharmaceuticals Advances NASH Treatment with Full Enrollment of MAESTRO-NASH OUTCOMES Trial Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced the appointment of Dr. Michael R. Charlton as Senior Vice President of Clinical Development, effective October 1, 2024. This key addition …
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as SVP of Clinical Development Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has revealed promising patient-reported outcomes showing that Rezdiffra (resmetirom) significantly enhances health-related quality of life (HRQL) for individuals with nonalcoholic steatohepatitis (NASH) with …
Madrigal Pharmaceuticals Announces Positive Quality of Life Outcomes for Rezdiffra in NASH Treatment Read More